Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635722 | 1.00 | SLC6A3 (0.47) | SLC6A3SLC6A4SLC6A2GRIN1GRIN2B | |
| SCHEMBL5636476 | 0.82 | DDB1 (0.46) | SLC6A3SLC6A2CHRM2CHRM1CHRM3 | |
| SCHEMBL14573359 | 0.82 | DDB1 (0.46) | SLC6A3SLC6A2CHRM2CHRM1CHRM3 | |
| SCHEMBL5636477 | 0.82 | DDB1 (0.46) | SLC6A3SLC6A2CHRM2CHRM1CHRM3 | |
| SCHEMBL7940536 | 0.80 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2CHRM1 | |
| SCHEMBL7940689 | 0.80 | CHRM1 (0.50) | SLC6A3SLC6A4SLC6A2GRIN1GRIN2B | |
| SCHEMBL5636304 | 0.80 | SLC6A2 (0.40) | SLC6A3SLC6A4SLC6A2DDB1CRBN | |
| SCHEMBL5636307 | 0.80 | SLC6A2 (0.40) | SLC6A3SLC6A4SLC6A2DDB1CRBN | |
| SCHEMBL5634899 | 0.80 | SLC6A2 (0.50) | SLC6A3SLC6A4SLC6A2CHRM2CHRM1 | |
| SCHEMBL5634904 | 0.80 | SLC6A2 (0.50) | SLC6A3SLC6A4SLC6A2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1597264-A2 | ANTIPARASITIC TERPENE ALKALOIDS | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1472248-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004072086-A2 | ANTIPARASITIC TERPENE ALKALOIDS | PFIZER LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003062235-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | SLC6A3 1580/4885SLC6A4 2221/4885SLC6A2 1939/4885 |
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | SLC6A3 71/4885SLC6A4 153/4885SLC6A2 46/4885 |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | SLC6A3 1519/4885SLC6A4 2045/4885SLC6A2 2111/4885 |
| US-20070054912-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | SLC6A3 284/4885SLC6A4 372/4885SLC6A2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.